WallStSmart

America Movil SAB de CV ADR (AMX)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

America Movil SAB de CV ADR generates 205% more annual revenue ($943.64B vs $309.06B). NVO leads profitability with a 33.1% profit margin vs 8.8%. AMX appears more attractively valued with a PEG of 1.17. AMX earns a higher WallStSmart Score of 69/100 (B-).

AMX

Strong Buy

69

out of 100

Grade: B-

Growth: 4.0Profit: 7.0Value: 10.0Quality: 4.0
Piotroski: 6/9Altman Z: 1.37

NVO

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 4.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMXUndervalued (+67.3%)

Margin of Safety

+67.3%

Fair Value

$72.07

Current Price

$24.76

$47.31 discount

UndervaluedFair: $72.07Overvalued
NVOSignificantly Overvalued (-59.4%)

Margin of Safety

-59.4%

Fair Value

$24.21

Current Price

$36.33

$12.12 premium

UndervaluedFair: $24.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMX5 strengths · Avg: 8.8/10
Free Cash FlowQuality
$42.68B10/10

Generating 42.7B in free cash flow

Market CapQuality
$70.61B9/10

Large-cap with strong market position

Return on EquityProfitability
20.5%9/10

Every $100 of equity generates 21 in profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Operating MarginProfitability
20.1%8/10

Strong operational efficiency at 20.1%

NVO5 strengths · Avg: 9.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
60.7%10/10

Every $100 of equity generates 61 in profit

Profit MarginProfitability
33.1%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
44.5%10/10

Strong operational efficiency at 44.5%

Market CapQuality
$165.02B9/10

Large-cap with strong market position

Areas to Watch

AMX4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.4%4/10

3.4% revenue growth

EPS GrowthGrowth
4.0%4/10

4.0% earnings growth

Price/BookValuation
72.8x2/10

Trading at 72.8x book value

Altman Z-ScoreHealth
1.372/10

Distress zone — elevated risk

NVO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

EPS GrowthGrowth
-4.7%2/10

Earnings declined 4.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMX

The strongest argument for AMX centers on Free Cash Flow, Market Cap, Return on Equity. PEG of 1.17 suggests the stock is reasonably priced for its growth.

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.

Bear Case : AMX

The primary concerns for AMX are Revenue Growth, EPS Growth, Price/Book. Debt-to-equity of 2.53 is elevated, increasing financial risk.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

AMX profiles as a value stock while NVO is a declining play — different risk/reward profiles.

AMX carries more volatility with a beta of 0.37 — expect wider price swings.

AMX is growing revenue faster at 3.4% — sustainability is the question.

AMX generates stronger free cash flow (42.7B), providing more financial flexibility.

Bottom Line

AMX scores higher overall (69/100 vs 55/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

America Movil SAB de CV ADR

COMMUNICATION SERVICES · TELECOM SERVICES · USA

Amrica Mvil, SAB de CV provides telecommunications services in Latin America and internationally. The company is headquartered in Mexico City, Mexico.

Visit Website →

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?